Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. ABEO has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
ABEO stock price ended at $6 on Wednesday, after rising0%
The Abeona Therapeutics Inc stock price increased by 0% on the last trading day (18 Jun 2025), rising from 6.02 to 6. Throughout the last trading session, the stock experienced a fluctuation of 3.54% , ranging from a day low of $5.93 to a day high of 6.14. The price has declined in 5 of the last 10 days, resulting in a total change of -6.83% during this period. On the last day, trading volume increase by -296.52K shares, with the rising prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 422.35K shares were traded, amounting to approximately 2.55M.
ABEO Technical Signals
ABEO(Abeona Therapeutics Inc Corp) has 5 buy signals and 3 sell signals now. The current trend is downtrend starting from 2025-06-09. The total price change during this trend is -8.26%. Recently, the price has increased but the volume has decreased, indicating a potential warning signal. The average turnover of ABEO over the last 5 trading days is 3.33M. Overall, the technical indicator signals lean more toward a Bullish outlook in the mid-term.
ABEO Moving Average Analysis
Abeona Therapeutics Inc's overall moving average trend leans more bearish as of Friday, June 20, 2025, with 3 negative signals and 1 positive signal. In the mid-term, the SMA_20 being above the SMA_60 signals a strong bullish trend. There will be some resistance from the lines at $6.9169833333333335, and $7.270333333333333. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $5.7736833333333335, and $5.420333333333334. A break-down below any of these levels will issue sell signals.
ABEO Short Selling Analysis
The short sale ratio of Abeona Therapeutics Inc(ABEO) as of 17 Jun 2025 is 27.65%, dropping from last trading day. With decreasing price from 5.96 to 6.00. The short sell activity indicate that short sellers may be experiencing short cover.
Technical Signal
Technical Signals Summary
Sell
3
Buy
5
Moving Average
Swing
Negative
Stock Price Below SMA_5
Short Term
Negative
SMA_5 Below SMA_20
Mid Term
Positive
SMA_20 Above SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
5 Bullish Signals
5 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Stochastic Oscillator %K (14, 3, 3)
STOCHk_14_3_3 < 20
7.757
Bullish
Commodity Channel Index (20 days, 0.015 constant)
CCI_20_0.015 < -100
-107.314
Bullish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 > 0
0.0636
Bullish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 < 20
3.157
Bullish
Williams %R (14 days)
WILLR_14 < -80
-90.811
Bullish
3 Bearish Signals
3 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 < 0
-0.0483
Bearish
Momentum (10 days)
MOM_10 < 0
-0.44
Bearish
Moving Average
10-day SMA crosses below 20-day SMA
--
Bearish
ABEO Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Abeona Therapeutics Inc(ABEO), our algorithm predicts ABEO's 1-month price at $6.14, with an -0.36%downwardshift. Using a similarity score up to 93.17%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Abeona Therapeutics Inc (ABEO.O) stock, as of Sunday, June 15, 2025 , forecasts a -0.36% change over the next month, based on its high correlation with ORCL.N stock patterns. The similarity between their price movements over the analyzed periods is 93.17%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
ABEO
No Data
ORCL
Down: -0.36%Similarity: 93.17%
Name
Similarity
Up/Down
ORCL.N
93.17%
-0.36%
EQIX.O
92.45%
+8.43%
CPAY.N
92.32%
-2.06%
NPO.N
91.76%
-11.42%
ARR.N
91.73%
-4.70%
TRVG.O
91.65%
+57.86%
ICMB.O
91.49%
+2.91%
MLR.N
91.35%
-5.97%
PRGO.N
91.25%
+4.43%
IVR.N
91.20%
+2.16%
ABEO Seasonality Analysis
Based on ABEO's historical stock price data across all years, the probability of a positive return in June is27.27%, suggesting it maynotbe an ideal month to invest in ABEO. In contrast,Apriloffers the highest probability of positive returns at63.64%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Abeona Therapeutics Inc (ABEO.O) stock in April has the highest probability of a positive return (63.64%), while January has the lowest probability (9.09%).
Performance Seasonality
The chart shows Abeona Therapeutics Inc. (ABEO)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy Abeona Therapeutics Inc (ABEO.O) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. ABEO has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
Which months have the highest win rate for buying Abeona Therapeutics Inc (ABEO.O) stock in a year?
The radar chart shows that buying Abeona Therapeutics Inc (ABEO.O) stock in April has the highest probability of a positive return (63.64%), while January has the lowest probability (9.09%).
How has Abeona Therapeutics Inc. (ABEO)'s stock price performed over the past three years?
ABEO's stock price rose by 75.17% in 2023,increased by 0.72% in 2024, and went up by 1.52% in 2025.
Bearish technical signals of ABEO include: AO_5_34 < 0, MOM_10 < 0, 10-day SMA crosses below 20-day SMA.
Is ABEO a buy based on overall technical signals summary?
ABEO has 5 buy signals and 3 sell signals now. Overall the technical rating for ABEO is Buy . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of ABEO.
What is the trend of Abeona Therapeutics Inc (ABEO)'s moving average?
Abeona Therapeutics Inc's overall moving average trend leans more bearish as of June 20 2025, with 3 negative signals and 1 positive signal.
What is price prediction for ABEO stock next month?
The price prediction chart for Abeona Therapeutics Inc (ABEO.O) stock, as of June 15 2025, forecasts a -0.36% change over the next month, based on its high correlation with ORCL stock patterns. The similarity between their price movements over the analyzed periods is 93.17%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for ABEO Stock?
### **Price Prediction for ABEO Stock in 2025**
ABEO stock is predicted to reach **$18** by the end of 2025.
This forecast is driven by the FDA approval of ZEVASKYN, strong cash position, and positive analyst sentiment.
What is price prediction 2030 for ABEO Stock?
ABEO stock is predicted to reach **$25 by 2030**, driven by the successful FDA approval of ZEVASKYN and its potential to dominate the market for recessive dystrophic epidermolysis bullosa treatments. The company's strong financial position and positive analyst sentiment further support this outlook.